Teppei Kitagawa
Beckman Coulter, Japan
Title: Optimization of Cell culturing condition and Cell quality control is Essential for Engineered T-cell Therapy
Biography
Biography: Teppei Kitagawa
Abstract
Immune therapy for cancer has started in 1900’s. However the immune system and understanding of their mechanisms were not elucidated so that the therapy couldn’t provide sufficient effect. Recent studies regarding cell biology and immune biology enabled us to design engineered immune cells using gene editing techniques.
Chimeric antigen receptor T cell therapy (CAR-T), one of cell therapies, is the therapy specific for cancer. T-cells derived from patient are engineered to express a synthetic receptor against specific cancer cells. The engineered T-cells are infused back into the patient’s blood stream. These engineered T-cells recognize cancer cells of the patient and trigger immune response.
To operate CAR-T cell therapy, high qualified CAR-T cells are required for effective cancer treatment. Beckman Coulter provides solutions for CAR-T cells manufacturing processes. Our technologies ensure manufacturing high qualified CAR-T cells (e.g. optimization of the cell culturing, controlling cell viability, checking the cell quality, and antigen receptor expression).
We, Beckman Coulter, explains our solution for optimization of making high qualified CAR-T cell in this session.